In a report by Fotheringham et al. (2009), it has been shown that high amounts of pre-treatment RAD23B in myeloma and cutaneous T-cell lymphoma cells are predictive of a high sensitivity to HDAC inhibitors [31]. The gene discussed is HDAC9; the disease is plasma cell myeloma.